Fisher Asset Management LLC Has $7.30 Million Holdings in Alkermes plc (NASDAQ:ALKS)

Fisher Asset Management LLC increased its stake in Alkermes plc (NASDAQ:ALKS) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 260,785 shares of the company’s stock after buying an additional 18,147 shares during the quarter. Fisher Asset Management LLC owned approximately 0.16% of Alkermes worth $7,299,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ALKS. Armistice Capital LLC boosted its holdings in shares of Alkermes by 301.5% in the 2nd quarter. Armistice Capital LLC now owns 2,699,179 shares of the company’s stock valued at $65,050,000 after buying an additional 2,026,961 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Alkermes by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company’s stock valued at $135,939,000 after buying an additional 1,362,079 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Alkermes by 87.1% in the 2nd quarter. American Century Companies Inc. now owns 2,203,456 shares of the company’s stock valued at $53,103,000 after buying an additional 1,025,905 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Alkermes by 766.7% in the 2nd quarter. Affinity Asset Advisors LLC now owns 650,000 shares of the company’s stock valued at $15,665,000 after buying an additional 575,000 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Alkermes by 89.4% in the 2nd quarter. AQR Capital Management LLC now owns 803,504 shares of the company’s stock valued at $19,364,000 after buying an additional 379,240 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 10,471 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the transaction, the executive vice president now owns 99,238 shares in the company, valued at approximately $2,930,498.14. This trade represents a 9.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the transaction, the senior vice president now owns 60,703 shares in the company, valued at $1,769,492.45. The trade was a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,675 shares of company stock worth $2,235,622. Company insiders own 4.89% of the company’s stock.

Alkermes Stock Up 0.2 %

Shares of NASDAQ ALKS opened at $29.32 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. Alkermes plc has a 52 week low of $22.22 and a 52 week high of $32.88. The stock has a market capitalization of $4.74 billion, a P/E ratio of 15.04, a PEG ratio of 0.98 and a beta of 0.47. The stock’s fifty day moving average is $28.00 and its 200 day moving average is $26.49.

Analysts Set New Price Targets

Several brokerages have issued reports on ALKS. The Goldman Sachs Group cut their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. cut their price target on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. Mizuho raised their price target on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Cantor Fitzgerald cut their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.42.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.